View Clinical Trial (Medical Research Study)
Ascending Dose Study of the Safety and Tolerability of REGN668(SAR231893) in Normal Healthy Volunteers - NCT01015027-(Clinical Trial 559167)
ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.
| City: |
|
Baltimore |
|
State:
|
|
MD |
| Zip Code: |
|
|
| Conditions: |
|
Healthy |
| Purpose: |
|
This study will test the safety and tolerability (how the body reacts to the drug) of
REGN668 and placebo (an inactive substance that contains no medicine) in healthy subjects.
|
| Study summary: |
|
|
| Criteria: |
|
Inclusion Criteria:
1. Male or female 18 to 65 years of age.
2. Weight > 50 kg and < 120 kg.
3. For women of childbearing potential, a negative serum pregnancy test at the screening
visit (visit 1) and a negative urine pregnancy test on day -1.
4. Willingness to refrain from the consumption of alcohol for 24 hours prior to each
study visit.
5. For men and women of childbearing potential, willingness to utilize adequate
contraception and not become pregnant (or have their partner[s] become pregnant)
during the full duration of the study.
6. Willing, committed, and able to return for ALL clinic visits and complete all
study-related procedures.
7. Able to read, understand and willing to sign the informed consent form.
Exclusion Criteria:
1. Onset of a new exercise routine or major change to a previous exercise routine within
4 weeks prior to screening visit.
2. Pregnant or breast-feeding women.
3. Significant concomitant illness or history of significant illness such as cardiac,
renal, neurological, endocrinological, metabolic or lymphatic disease, or any other
illness or condition that would adversely affect the subject's participation in this
study.
4. Hospitalization for any reason within 60 days of screening (visit 1).
5. Known history of Human Immunodeficiency Virus (HIV), Hepatitis B or Hepatitis C,
and/or positive Hepatitis B surface antigen (HBsAg), positive Hepatitis C antibody
(HCV).
6. Previous exposure to any therapeutic or investigational biological agent. results.
7. History of alcohol or substance abuse within previous 5 years. |
|
|
|
|
|
|
|
|
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
|
| Trials Alerts: |
|
If you would like to be
notified of new clinical trials as they become available please
register for a free account.
|
|
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
August 16, 2010 |
Modifications to
this listing: |
|
Only selected fields are shown, please use the link
above to view all information about this clinical trial. |
|
|
|
|
|
|
|
|